Goldman Sachs
SABS icon

Goldman Sachs’s SAB Biotherapeutics SABS Stock Holding History

Goldman Sachs’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$746K Buy
191,305
+77,365
+68% +$288K ﹤0.01% 5442
2026
Q1 		$436K Buy
113,940
+62,592
+122% +$250K ﹤0.01% 5681
2025
Q4 		$192K Buy
51,348
+40,127
+358% +$132K ﹤0.01% 6052
2025
Q3 		$22.6K Buy
+11,221
New +$25.4K ﹤0.01% 6231
2022
Q4 		– Sell
-1,262
Closed -$9K – 6235
2022
Q3 		$9K Sell
1,262
-184
-13% -$1.83K ﹤0.01% 6036
2022
Q2 		$21K Sell
1,446
-103
-7% -$2.16K ﹤0.01% 6161
2022
Q1 		$58K Buy
1,549
+100
+7% +$4.62K ﹤0.01% 6239
2021
Q4 		$113K Sell
1,449
-4,051
-74% -$380K ﹤0.01% 6101
2021
Q3 		$554K Sell
5,500
-1,842
-25% -$184K ﹤0.01% 5136
2021
Q2 		$731K Hold
7,342
– – ﹤0.01% 4989
2021
Q1 		$721K Buy
+7,342
New +$734K ﹤0.01% 4855

Other funds holding SABS

Caligan Partners
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vivo Capital
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Commodore Capital
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Goldman Sachs's SABS Position: Q2 2026 in Review

Goldman Sachs increased its SAB Biotherapeutics (SABS) stake by 68% in Q2 2026, buying an estimated $288K and bringing the position to 191,305 shares worth $746K. The position accounts for ﹤0.01% of the portfolio, ranked #5442.

Goldman Sachs first reported a position in SABS in Q1 2021 and has held it in 11 quarters since. 87 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

  • Goldman Sachs held 191,305 shares of SAB Biotherapeutics worth $746K as of Q2 2026.
  • Goldman Sachs bought 77,365 SAB Biotherapeutics shares in Q2 2026, an estimated $288K.
  • SAB Biotherapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #5442 holding.
  • Goldman Sachs first reported a position in SAB Biotherapeutics in Q1 2021 and has held it in 11 quarters since.
  • 87 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.